BMS-986528

N/A

Report date: 2026/05/28 20:00:21

Base Information

Drug NameBMS-986528
Drug Alias NameBMS-986528
ClassificationBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulators
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBristol Myers Squibb Srlcompany
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A